Impact of low-density lipoprotein particle size on carotid intima-media thickness in patients with type 2 diabetes mellitus

Metabolism: Clinical and Experimental

Volumn 56, Issue 5, 2007, Pages 608-613

  Hayashi, Yuzo ^a   Okumura, Kenji ^a   Matsui, Hideo ^a   Imamura, Akiko ^a   Miura, Manabu ^a   Takahashi, Ryotaro ^a   Murakami, Ryuichiro ^a   Ogawa, Yasuhiro ^a   Numaguchi, Yasushi ^b   Murohara, Toyoaki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; CAROTID ARTERY; CORRELATION ANALYSIS; ECHOGRAPHY; FEMALE; GLYCATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PARTICLE SIZE; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STATISTICAL ANALYSIS; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; CAROTID ARTERY, COMMON; CHOLESTEROL, HDL; CORONARY ARTERIOSCLEROSIS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; LIPOPROTEINS, LDL; MALE; MALONDIALDEHYDE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PARTICLE SIZE; TUNICA INTIMA; ULTRASONOGRAPHY;

EID: 34147136501     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2007.01.001     Document Type: Article

References (35)

1. Shen M.M., Krauss R.M., Lindgren F.T., and Forte T.M. Heterogeneity of serum low density lipoproteins in normal human subjects. J Lipid Res 22 (1981) 236-244
2. Chancharme L., Therond P., Nigon F., Lepage S., Couturier M., and Chapman M.J. Cholesteryl ester hydroperoxide lability is a key feature of the oxidative susceptibility of small, dense LDL. Arterioscler Thromb Vasc Biol 19 (1999) 810-820
3. Austin M.A., Breslow J.L., Hennekens C.H., Buring J.E., Willett W.C., and Krauss R.M. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 260 (1988) 1917-1921
4. Campos H., Genest Jr. J.J., Blijlevens E., et al. Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb 12 (1992) 187-195
5. Erbey J.R., Robbins D., Forrest K.Y., and Orchard T.J. Low density lipoprotein size and coronary disease in a childhood-onset type 1 diabetes population. Metabolism 48 (1999) 531-534
6. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., and Witztum J.L. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320 (1989) 915-924
7. Berliner J.A., and Heinecke J.W. The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med 20 (1996) 707-727
8. Liu M.L., Ylitalo K., Salonen R., Salonen J.T., and Taskinen M.R. Circulating oxidized low-density lipoprotein and its association with carotid intima-media thickness in asymptomatic members of familial combined hyperlipidemia families. Arterioscler Thromb Vasc Biol 24 (2004) 1492-1497
9. Graier W.F., and Kostner G.M. Glycated low-density lipoprotein and atherogenesis: the missing link between diabetes mellitus and hypercholesterolaemia?. Eur J Clin Invest 27 (1997) 457-459
10. Kannel W.B. Lipids, diabetes, and coronary heart disease: insights from the Framingham Study. Am Heart J 110 (1985) 1100-1107
11. Moro E., Alessandrini P., Zambon C., et al. Is glycation of low density lipoproteins in patients with type 2 diabetes mellitus a LDL pre-oxidative condition?. Diabet Med 16 (1999) 663-669
12. Berneis K., Jeanneret C., Muser J., Felix B., and Miserez A.R. Low-density lipoprotein size and subclasses are markers of clinically apparent and non-apparent atherosclerosis in type 2 diabetes. Metabolism 54 (2005) 227-234
13. Salonen J.T., and Salonen R. Ultrasound B-mode imaging in observational studies of atherosclerotic progression. Circulation 87 3 Suppl (1993) II56-II65
14. Chambless L.E., Heiss G., Folsom A.R., et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol 146 (1997) 483-494
15. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment; insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
16. Okumura K., Matsui H., Kawakami K., et al. Low density lipoprotein particle size is associated with glycosylated hemoglobin levels regardless of plasma lipid levels. Intern Med 37 (1998) 273-279
17. Krauss R.M., and Burke D.J. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res 23 (1982) 97-104
18. Kotani K., Maekawa M., Kanno T., Kondo A., Toda N., and Manabe M. Distribution of immunoreactive malondialdehyde-modified low-density lipoprotein in human serum. Biochim Biophys Acta 1215 (1994) 121-125
19. Shea E.A., and Cohen M.P. Immunologic detection and measurement of glycated apolipoprotein B with site specific monoclonal antibodies. J Immunol Methods 162 (1993) 85-95
20. Baldassarre D., Amato M., Pustina L., et al. Increased carotid artery intima-media thickness in subjects with primary hypoalphalipoproteinemia. Arterioscler Thromb Vasc Biol 22 (2002) 317-322
21. Kodama M., Yamasaki Y., Sakamoto K., et al. Antiplatelet drugs attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. Thromb Res 97 (2000) 239-245
22. Hosomi N., Mizushige K., Ohyama H., et al. Angiotensin-converting enzyme inhibition with enalapril slows progressive intima-media thickening of the common carotid artery in patients with non-insulin-dependent diabetes mellitus. Stroke 32 (2001) 1539-1545
23. Goya K., Kitamura T., Inaba M., et al. Risk factors for asymptomatic atherosclerosis in Japanese type 2 diabetic patients without diabetic microvascular complications. Metabolism 52 (2003) 1302-1306
24. Lamarche B., Tchernof A., Moorjani S., et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: prospective results from the Quebec cardiovascular study. Circulation 95 (1997) 69-75
25. Reaven G.M., Chen Y.D., Jeppesen J., Maheux P., and Krauss R.M. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Invest 92 (1993) 141-146
26. Mykkanen L., Haffner S.M., Rainwater D.L., Karhapaa P., Miettinenn H., and Laakso M. Relationship of LDL size to insulin sensitivity in normoglycemic men. Arterioscler Thromb Vasc Biol 17 (1997) 1447-1453
27. Singh A.T., Rainwater D.L., Haffner S.M., et al. Effect of diabetes on lipoprotein size. Arterioscler Thromb Vasc Biol 15 (1995) 1805-1811
28. Katzel L.I., Coon P.J., Rogus E., Krauss R.M., and Goldberg A.P. Persistence of low HDL-C levels after weight reduction in older men with small LDL particles. Arterioscler Thromb Vasc Biol 15 (1995) 299-305
29. Matsui H., Okumura K., Toki Y., and Hayakawa T. Low-density lipoprotein particle size as an independent predictor of glycated low-density lipoprotein level. Diabetes Care 7 (1999) 1220-1221
30. Brousseau M.E., Schaefer E.J., Wolfe M.L., et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 350 (2004) 1505-1515
31. Shishehbor M.H., Brennan M.L., Aviles R.J., et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 108 (2003) 426-431
32. Okumura K., Matsui H., Kamiya H., Saburi Y., Hayashi K., and Hayakawa T. Differential effect of two common polymorphisms in the cholesteryl ester transfer protein gene on low-density lipoprotein particle size. Atherosclerosis 161 (2002) 425-431
33. Okumura K., Matsui H., Ogawa Y., et al. The polymorphism of the beta3-adrenergic receptor gene is associated with reduced low-density lipoprotein particle size. Metabolism 52 (2003) 356-361
34. Kadowaki T., Miyake Y., Hagura R., et al. Risk factors for worsening to diabetes in subjects with impaired glucose tolerance. Diabetologia 26 (1984) 44-49
35. Sasahara M., Nishi M., Kawashima H., et al. Uncoupling protein 2 promoter polymorphism-866G/A affects its expression in β-cells and modulates clinical profiles of Japanese type 2 diabetic patients. Diabetes 53 (2004) 482-485